MIAMI BEACH, Fla. — Patients with atopic dermatitis resistant to systemic therapy, including dupilumab, may benefit from tralokinumab treatment, according to a poster presentation here.
Elena Pezzolo, MD, of the department of dermatology at San Bortolo Hospital and the Study Center of the Italian Group for the Epidemiologic Research in Dermatology in Italy, won this year’s poster competition at South Beach Symposium for her research on the efficacy and safety profile of tralokinumab in patients with moderate to severe AD that were resistant to systemic therapies, including